Acquired bullous disease

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Key Features: Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes and has three major forms: pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. It is characterized histologically by intraepi-thelial blister formation caused by the loss of cell-to-cell adhesion of keratinocytes (acan-tholysis) and immunopathologically by the presence of tissue-bound and circulating IgG autoantibodies directed against the cell surface of keratinocytes or desmogleins. Desmogleins (Dsg1 and Dsg3) are the target antigens in pemphigus, and the clinical pheno-type is correlated with the patient's antides-moglein autoantibody profile. Paraneoplastic pemphigus occurs in association with underlying neoplasms and shows severe oral and conjunctival erosions with polymorphous skin eruptions. Paraneoplastic pemphigus is caused by humoral (IgG autoan-tibodies against Dsg3, Dsg1, and plakin molecules), as well as cellular, autoimmunity. Bulbous pemphigoid is a subepidermal autoimmune blistering disease that most commonly occurs in the elderly. The clinical presentation is typically a pruritic eruption with widespread tense blisters. It is immunopathologically characterized by in vivo bound IgG and C3 at the dermoepidermal junction. The target antigens in bullous pemphigoid are BP230(BPAG1 or BP230) and BP180(BPAG2 or type XVII collagen), which are found in hemidesmosomes along the basement membrane zone. Epidermolysis bullous acquisita is a rare and acquired bullous disease associated with IgG autoantibodies against type VII collagen, which is the major component of anchoring fibrils. Systemic corticosteroids are the mainstay of therapy for acquired autoimmune bullous disease, and adjuvant therapies, including immunosup-pressive agents, plasmapheresis, high-dose intravenous immunogloblin, and biological agents, are used for severe cases.

Original languageEnglish
Title of host publicationTherapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis
PublisherSpringer Berlin Heidelberg
Pages389-405
Number of pages17
ISBN (Print)9783540788133
DOIs
Publication statusPublished - 2010

Fingerprint

Pemphigus
Desmogleins
Immunoglobulin G
Autoantibodies
Autoimmune Diseases
Bullous Pemphigoid
Blister
Keratinocytes
Collagen Type VII
Hemidesmosomes
Antigens
Skin
Plasmapheresis
Biological Factors
Autoimmunity
Basement Membrane
Cell Adhesion
Adrenal Cortex Hormones
Mucous Membrane
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tanikawa, A., & Amagai, M. (2010). Acquired bullous disease. In Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis (pp. 389-405). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-540-78814-0_36

Acquired bullous disease. / Tanikawa, Akiko; Amagai, Masayuki.

Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis. Springer Berlin Heidelberg, 2010. p. 389-405.

Research output: Chapter in Book/Report/Conference proceedingChapter

Tanikawa, A & Amagai, M 2010, Acquired bullous disease. in Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis. Springer Berlin Heidelberg, pp. 389-405. https://doi.org/10.1007/978-3-540-78814-0_36
Tanikawa A, Amagai M. Acquired bullous disease. In Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis. Springer Berlin Heidelberg. 2010. p. 389-405 https://doi.org/10.1007/978-3-540-78814-0_36
Tanikawa, Akiko ; Amagai, Masayuki. / Acquired bullous disease. Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis. Springer Berlin Heidelberg, 2010. pp. 389-405
@inbook{e844599116964382992afec902989876,
title = "Acquired bullous disease",
abstract = "Key Features: Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes and has three major forms: pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. It is characterized histologically by intraepi-thelial blister formation caused by the loss of cell-to-cell adhesion of keratinocytes (acan-tholysis) and immunopathologically by the presence of tissue-bound and circulating IgG autoantibodies directed against the cell surface of keratinocytes or desmogleins. Desmogleins (Dsg1 and Dsg3) are the target antigens in pemphigus, and the clinical pheno-type is correlated with the patient's antides-moglein autoantibody profile. Paraneoplastic pemphigus occurs in association with underlying neoplasms and shows severe oral and conjunctival erosions with polymorphous skin eruptions. Paraneoplastic pemphigus is caused by humoral (IgG autoan-tibodies against Dsg3, Dsg1, and plakin molecules), as well as cellular, autoimmunity. Bulbous pemphigoid is a subepidermal autoimmune blistering disease that most commonly occurs in the elderly. The clinical presentation is typically a pruritic eruption with widespread tense blisters. It is immunopathologically characterized by in vivo bound IgG and C3 at the dermoepidermal junction. The target antigens in bullous pemphigoid are BP230(BPAG1 or BP230) and BP180(BPAG2 or type XVII collagen), which are found in hemidesmosomes along the basement membrane zone. Epidermolysis bullous acquisita is a rare and acquired bullous disease associated with IgG autoantibodies against type VII collagen, which is the major component of anchoring fibrils. Systemic corticosteroids are the mainstay of therapy for acquired autoimmune bullous disease, and adjuvant therapies, including immunosup-pressive agents, plasmapheresis, high-dose intravenous immunogloblin, and biological agents, are used for severe cases.",
author = "Akiko Tanikawa and Masayuki Amagai",
year = "2010",
doi = "10.1007/978-3-540-78814-0_36",
language = "English",
isbn = "9783540788133",
pages = "389--405",
booktitle = "Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Acquired bullous disease

AU - Tanikawa, Akiko

AU - Amagai, Masayuki

PY - 2010

Y1 - 2010

N2 - Key Features: Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes and has three major forms: pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. It is characterized histologically by intraepi-thelial blister formation caused by the loss of cell-to-cell adhesion of keratinocytes (acan-tholysis) and immunopathologically by the presence of tissue-bound and circulating IgG autoantibodies directed against the cell surface of keratinocytes or desmogleins. Desmogleins (Dsg1 and Dsg3) are the target antigens in pemphigus, and the clinical pheno-type is correlated with the patient's antides-moglein autoantibody profile. Paraneoplastic pemphigus occurs in association with underlying neoplasms and shows severe oral and conjunctival erosions with polymorphous skin eruptions. Paraneoplastic pemphigus is caused by humoral (IgG autoan-tibodies against Dsg3, Dsg1, and plakin molecules), as well as cellular, autoimmunity. Bulbous pemphigoid is a subepidermal autoimmune blistering disease that most commonly occurs in the elderly. The clinical presentation is typically a pruritic eruption with widespread tense blisters. It is immunopathologically characterized by in vivo bound IgG and C3 at the dermoepidermal junction. The target antigens in bullous pemphigoid are BP230(BPAG1 or BP230) and BP180(BPAG2 or type XVII collagen), which are found in hemidesmosomes along the basement membrane zone. Epidermolysis bullous acquisita is a rare and acquired bullous disease associated with IgG autoantibodies against type VII collagen, which is the major component of anchoring fibrils. Systemic corticosteroids are the mainstay of therapy for acquired autoimmune bullous disease, and adjuvant therapies, including immunosup-pressive agents, plasmapheresis, high-dose intravenous immunogloblin, and biological agents, are used for severe cases.

AB - Key Features: Pemphigus is a group of autoimmune blistering diseases that affect the skin and mucous membranes and has three major forms: pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. It is characterized histologically by intraepi-thelial blister formation caused by the loss of cell-to-cell adhesion of keratinocytes (acan-tholysis) and immunopathologically by the presence of tissue-bound and circulating IgG autoantibodies directed against the cell surface of keratinocytes or desmogleins. Desmogleins (Dsg1 and Dsg3) are the target antigens in pemphigus, and the clinical pheno-type is correlated with the patient's antides-moglein autoantibody profile. Paraneoplastic pemphigus occurs in association with underlying neoplasms and shows severe oral and conjunctival erosions with polymorphous skin eruptions. Paraneoplastic pemphigus is caused by humoral (IgG autoan-tibodies against Dsg3, Dsg1, and plakin molecules), as well as cellular, autoimmunity. Bulbous pemphigoid is a subepidermal autoimmune blistering disease that most commonly occurs in the elderly. The clinical presentation is typically a pruritic eruption with widespread tense blisters. It is immunopathologically characterized by in vivo bound IgG and C3 at the dermoepidermal junction. The target antigens in bullous pemphigoid are BP230(BPAG1 or BP230) and BP180(BPAG2 or type XVII collagen), which are found in hemidesmosomes along the basement membrane zone. Epidermolysis bullous acquisita is a rare and acquired bullous disease associated with IgG autoantibodies against type VII collagen, which is the major component of anchoring fibrils. Systemic corticosteroids are the mainstay of therapy for acquired autoimmune bullous disease, and adjuvant therapies, including immunosup-pressive agents, plasmapheresis, high-dose intravenous immunogloblin, and biological agents, are used for severe cases.

UR - http://www.scopus.com/inward/record.url?scp=84892107228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892107228&partnerID=8YFLogxK

U2 - 10.1007/978-3-540-78814-0_36

DO - 10.1007/978-3-540-78814-0_36

M3 - Chapter

SN - 9783540788133

SP - 389

EP - 405

BT - Therapy of Skin Diseases: A Worldwide Perspective on Therapeutic Approaches and Their Molecular Basis

PB - Springer Berlin Heidelberg

ER -